This webinar will explore the critical role of genetic alterations in cancer development and treatment. Participants will gain a comprehensive understanding of the differences between inherited (germline) and acquired (somatic) mutations, their implications for precision oncology, and how to effectively detect them. The program will also highlight the tools and methodologies used to detect these genetic changes and provide strategies for collaborating with genetic counselors to incorporate hereditary risk assessments into cancer diagnosis and management.

February 1, 2025

Theresa Boyle, MD, PhD
Associate Member
Medical Director, Molecular Solid Tumor
Moffitt Cancer Center and Research Institute



Christine Walko, PharmD
Senior Member, Department of Pathology
Attending, Precision Medicine Clinical Service
Moffitt Cancer Center

This program is designed for pathologists.

At the conclusion of this activity, learners should be better able to:
• Differentiate between oncogenic germline and somatic alterations (eg, BRCA, HRD).
• Review how germline and somatic alterations may be detected.
• Collaborate with genetic counselors to integrate hereditary risk assessment into cancer diagnosis.

Support for this accredited continuing education activity has been made possible through educational grants from AstraZeneca and Daiichi Sankyo.

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Florida Society of Pathologists (FSP). American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals
Other members of the care team will receive a certificate of participation.

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the program evaluation.

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Faculty/Planner:
Theresa Boyle, MD, PhD: Discloses the following relevant financial relationships:
Grant/Research Support: Bristol Myers Squibb
Speaker’s Bureau: Bristol Myers Squibb

Christine Walko, PharmD has no relevant financial relationships with ineligible companies to disclose.

Planners:
John JD Juchniewicz, MCIS, CHCP, FACEHP - American Academy of CME: No relevant financial relationships with ineligible companies to disclose.
Erin Corrales - Florida Society of Pathologists: No relevant financial relationships with ineligible companies to disclose.
Joseph Kim, MD – Florida Society of Pathologists: No relevant financial relationships with ineligible companies to disclose.
Marilyn Bui, MD, PhD – Florida Society of Pathologists: Discloses the following relevant financial relationships:
Advisory Board/Consultant: Visiopharm, Aiforia, Roche, AstraZeneca, PathAI, DigitCells, Merck.

The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy or Florida Society of Pathologists. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information. This activity may contain discussion of unlabeled/investigational usage.